Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia.

Parigger, T; Gassner, FJ; Scherhaufl, C; Abu Bakar, A; Hopner, JP; Hodlmoser, A; Steiner, M; Catakovic, K; Geisberger, R; Greil, R; Zaborsky, N. Int J Mol Sci. 2021 Jun 22;22(13):6648. doi: 10.3390/ijms22136648.

Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.

Aftimos, P; Oliveira, M; Irrthum, A; Fumagalli, D; Sotiriou, C; Gal-Yam, EN; Robson, ME; Ndozeng, J; Di Leo, A; Ciruelos, EM; de Azambuja, E; Viale, G; Scheepers, ED; Curigliano, G; Bliss, JM; Reis, JS; Colleoni, M; Balic, M; Cardoso, F; Albanell, J; Duhem, C; Marreaud, S; Romagnoli, D; Rojas, B; Gombos, A; Wildiers, H; Guerrero-Zotano, A; Hall, P; Bonetti, A; Larsson, KF; Degiorgis, M; Khodaverdi, S; Greil, R; Sverrisdottir, A; Paoli, M; Seyll, E; Loibl, S; Linderholm, B; Zoppoli, G; Davidson, NE; Johannsson, OT; Bedard, PL; Loi, S; Knox, S; Cameron, DA; Harbeck, N; Montoya, ML; Brandao, M; Vingiani, A; Caballero, C; Hilbers, FS; Yates, LR; Benelli, M; Venet, D; Piccart, MJ. Cancer Discov. 2021 Nov;11(11):2796-2811. doi: 10.1158/2159-8290.CD-20-1647. Epub 2021 Jun 28.

Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators.

Rauscher, S; Greil, R; Geisberger, R. Curr Cancer Drug Targets. 2021;21(4):353-359. doi: 10.2174/1568009620666210108102723.

AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL.

Schubert, M; Gassner, FJ; Huemer, M; Hopner, JP; Akimova, E; Steiner, M; Egle, A; Greil, R; Zaborsky, N; Geisberger, R. Cancers (Basel). 2021 May 26;13(11):2619. doi: 10.3390/cancers13112619.

Measurable residual disease in chronic lymphocytic leukemia: expert re-view and consensus recommendations.

Wierda, WG; Rawstron, A; Cymbalista, F; Badoux, X; Rossi, D; Brown, JR; Egle, A; Abello, V; Ceballos, EC; Herishanu, Y; Mulligan, SP; Niemann, CU; Diong, CP; Soysal, T; Suzuki, R; Tran, HTT; Wu, SJ; Owen, C; Stilgenbauer, S; Ghia, P; Hillmen, P. Leukemia. 2021 Jun 24. doi: 10.1038/s41375-021-01241-1. Online ahead of print.

Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Gampenrieder, SP; Pircher, M; Fesl, C; Rinnerthaler, G; Mlineritsch, B; Greil-Ressler, S; Steger, GG; Sagaster, V; Fitzal, F; Exner, R; Devyatko, Y; Balic, M; Stoger, H; Suppan, C; Bauernhofer, T; Singer, CF; Pfeiler, G; Seifert, M; Helfgott, R; Heck, D; Rumpold, H; Kwasny, W; Wieder, U; Gnant, M; Greil, R. BREAST CARE. 2021; https://doi.org/10.1159/000516157

The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer.

Leeksma AC, Derks IAM, Kasem MH, Kilic E, de Klein A, Jager MJ, van de Loosdrecht AA, Jansen JH, Navrkalova V, Faber LM, Zaborsky N, Egle A, Zenz T, Pospisilova S, Abdel-Wahab O, Kater AP, Eldering E. Front Oncol. 2021 Jan 29;10:609409. doi: 10.3389/fonc.2020.609409. eCollection 2020.

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).

Hecht, JR; Lonardi, S; Bendell, J; Sim, HW; Macarulla, T; Lopez, CD; Van Cutsem, E; Martin, AJM; Park, JO; Greil, R; Wang, H; Hozak, RR; Gueorguieva, I; Lin, Y; Rao, S; Ryoo, BY. J Clin Oncol. 2021 Apr 1;39(10):1108-1118. doi: 10.1200/JCO.20.02232. Epub 2021 Feb 8.

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.

Gnant, M; Fitzal, F; Rinnerthaler, G; Steger, GG; Greil-Ressler, S; Balic, M; Heck, D; Jakesz, R; Thaler, J; Egle, D; Manfreda, D; Bjelic-Radisic, V; Wieder, U; Singer, CF; Melbinger-Zeinitzer, E; Haslbauer, F; Sevelda, P; Trapl, H; Wette, V; Wimmer, K; Gampenrieder, SP; Bartsch, R; Kacerovsky-Strobl, S; Suppan, C; Brunner, C; Deutschmann, C; Soelkner, L; Fesl, C; Greil, R. N Engl J Med. 2021 Jul 29;385(5):395-405. doi: 10.1056/NEJMoa2104162.

Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP.

Bernard, S; Ghesquieres, H; Casasnovas, RO; Griolet, S; da Silva, MG; Feugier, P; Morschhauser, F; Trotman, J; Renaud, L; Greil, R; Garcia-Sancho, AM; Grosicki, S; van Eygen, K; Copie-Bergman, C; Haioun, C; Thieblemont, C. Blood Adv. 2021 Aug 10;5(15):2965-2968. doi: 10.1182/bloodadvances.2021004766.